
FDA ApprovedUnited States
New Weekly Infusion for Children with Hunter Syndrome
Avlayah (tividenofusp alfa-eknm) for neurologic Hunter syndrome (MPS II)
FDA accelerated approval (24 March 2026 letter; press 25 March 2026) for Avlayah (tividenofusp alfa-eknm) — a once-weekly IV enzyme…
FDA accelerated approval (24 March 2026 letter; press 25 March 2026) for Avlayah (tividenofusp…